Table 3.

MRI measurements over the first 24 weeks of the lenercept MS trial

VariablePlacebo, n = 43Lenercept, mgp Value
10, n = 4450, n = 40100, n = 40
* Analysis of variance of Ln(1 + x).
† Kruskal-Wallis test.
Newly active lesions, mean Median (range)8.9 4.0 (0–92)8.2 3.0 (0–55)15.5 5.5 (0–124)12.0 4.5 (0–102)0.43*
Persistently active lesions, mean Median (range)6.2 1.0 (0–100)3.3 1.0 (0–49)9.6 1.0 (0–128)3.3 1.0 (0–24)0.36*
Percent of active scans, mean Median (range)45.6 50 (0–100)40.6 33 (0–100)51.6 50 (0–100)49.2 55 (0–100)0.58
Percent change in burden of disease, mean Median (range)6.0 −2.2 (−28.8–280.9)9.9 0.0 (−30.5–251.0)4.3 1.4 (−35.2–62.8)4.9 −0.2 (−36.0–81.4)0.74